International Journal of Hematology

, Volume 96, Issue 1, pp 65–73

Down-regulation of hematopoiesis master regulator PU.1 via aberrant methylation in chronic myeloid leukemia

  • Hui Yang
  • Hui Liang
  • Jing-song Yan
  • Rong Tao
  • Si-guo Hao
  • Li-yuan Ma
Original Article


The PU.1 transcription factor is a crucial regulator of hematopoiesis, and its expression is altered in various leukemic processes. It has been shown that expression of PU.1 is severely impaired in patients with chronic myeloid leukemia (CML), but the mechanism underlying this effect remains unknown. Through bisulfite sequencing, semi-quantitative PCR, and indirect immunofluorescence and Western blot techniques, we found aberrant methylation in the promoter region of transcription factor PU.1 in CML patients both in the chronic and blast crisis phases, as well as in the CML blast K562 cell line. Of these, several CpG sites were more highly methylated in blast crisis than chronic phase, while no methylation of these sites was observed in healthy individuals. Interestingly, CML patients achieved complete cytogenetic remission under imatinib mesylate treatment, but the aberrant methylation status of PU.1 was not reversed. Down-regulation of PU.1 expression at the mRNA and protein levels was also observed in association with aberrant methylation. Thus, for the first time, we have revealed a potential epigenetic modification of PU.1 in CML, which may be responsible for the down-regulation of PU.1. These data suggest that aberrant methylation of PU.1 may play a role in CML pathogenesis, and may therefore serve as a useful biomarker and potential target for demethylating drugs.


Chronic myeloid leukemia Transcription factor PU.1 DNA methylation 


  1. 1.
    Quintás-Cardama A, Cortes JE. Chronic myeloid leukemia: diagnosis and treatment. Mayo Clin Proc. 2006;81(7):973–88.PubMedCrossRefGoogle Scholar
  2. 2.
    Ito T, Nishiyama C, Nakano N, et al. Roles of PU.1 in monocyte- and mast cell-specific gene regulation: PU.1 transactivates CIITA pIV in cooperation with IFN-gamma. Int Immunol. 2009;21(7):803–16.PubMedCrossRefGoogle Scholar
  3. 3.
    Oikawa T, Yamada T, Kihara-Negishi F, et al. The role of Ets family transcription factor PU.1 in hematopoietic cell differentiation, proliferation and apoptosis. Cell Death Differ. 1999;6(7):599–608.PubMedCrossRefGoogle Scholar
  4. 4.
    Kosmider O, Denis N, Lacout C, et al. Kit-activating mutations cooperate with Spi-1/PU.1 overexpression to promote tumorigenic progression during erythroleukemia in mice. Cancer Cell. 2005;8(6):467–78.PubMedCrossRefGoogle Scholar
  5. 5.
    Dakic A, Wu L, Nutt SL. Is PU.1 a dosage-sensitive regulator of haemopoietic lineage commitment and leukaemogenesis? Trends Immunol. 2007;28(3):108–14.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosenbauer F, Wagner K, Kutok JL, et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet. 2004;36(6):624–30.PubMedCrossRefGoogle Scholar
  7. 7.
    Zhang S-J, Ma L-Y, Huang Q-H, et al. Gain-of-function mutation of GATA-2 in acute myeloid transformation of chronic myeloid leukemia. Proc Natl Acad Sci USA. 2008;105(6):2076–81.PubMedCrossRefGoogle Scholar
  8. 8.
    Albajar M, Gutierrez P, Richard C, et al. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Lett. 2008;270(2):328–36.PubMedCrossRefGoogle Scholar
  9. 9.
    Plass C, Soloway PD. DNA methylation, imprinting and cancer. Eur J Hum Genet. 2002;10(1):6–16.PubMedCrossRefGoogle Scholar
  10. 10.
    Kinoshita T. Epigenetic inactivation of tumor suppressor genes in hematologic malignancies. Int J Hematol. 2004;80(2):108–19.PubMedCrossRefGoogle Scholar
  11. 11.
    Yang MY, Chang JG, Lin PM, et al. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci. 2006;97(12):1298–307.PubMedCrossRefGoogle Scholar
  12. 12.
    Nguyen TT, Mohrbacher AF, Tsai YC, et al. Quantitative measure of c-abl and p15 methylation in chronic myelogenous leukemia: biological implications. Blood. 2000;95(9):2990–2.PubMedGoogle Scholar
  13. 13.
    Yang MY, Liu TC, Chang JG, et al. JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood. 2003;101(8):3205–11.PubMedCrossRefGoogle Scholar
  14. 14.
    Liu TC, Lin SF, Chang JG, et al. Epigenetic alteration of the SOCS1 gene in chronic myeloid leukaemia. Br J Haematol. 2003;123(4):654–61.PubMedCrossRefGoogle Scholar
  15. 15.
    Tatetsu H, Ueno S, Hata H, et al. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res. 2007;67(11):5328–36.PubMedCrossRefGoogle Scholar
  16. 16.
    Dakic A, Metcalf D, Di Rago L, et al. PU.1 regulates the commitment of adult hematopoietic progenitors and restricts granulopoiesis. J Exp Med. 2005;201(9):1487–502.PubMedCrossRefGoogle Scholar
  17. 17.
    Chou ST, Khandros E, Bailey LC, et al. Graded repression of PU.1/Sfpi1 gene transcription by GATA factors regulates hematopoietic cell fate. Blood. 2009;114(5):983–94.PubMedCrossRefGoogle Scholar
  18. 18.
    DeKoter RP, Schweitzer BL, Kamath MB, et al. Regulation of the interleukin-7 receptor alpha promoter by the Ets transcription factors PU.1 and GA-binding protein in developing B cells. J Biol Chem. 2007;282(19):14194–204.PubMedCrossRefGoogle Scholar
  19. 19.
    Kastner P, Chan S. PU.1: a crucial and versatile player in hematopoiesis and leukemia. Int J Biochem Cell Biol. 2008;40(1):22–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Cook WD, McCaw BJ, Herring C, et al. PU.1 is a suppressor of myeloid leukemia, inactivated in mice by gene deletion and mutation of its DNA binding domain. Blood. 2004;104(12):3437–44.PubMedCrossRefGoogle Scholar
  21. 21.
    Mueller BU, Pabst T, Osato M, et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood. 2002;100(3):998–1007.PubMedCrossRefGoogle Scholar
  22. 22.
    Metcalf D, Dakic A, Mifsud S, et al. Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia. Proc Natl Acad Sci USA. 2006;103(5):1486–91.PubMedCrossRefGoogle Scholar
  23. 23.
    Vangala RK, Heiss-Neumann MS, Rangatia JS, et al. The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia. Blood. 2003;101(1):270–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang KK, Shi JT, Wang P, Zhu XH, He MM, Fang H, Du YZ, Zhang J. PML/RARalpha targets promoter regions containing PU.1 consensus and RARE half sites in acute promyelocytic leukemia. Cancer Cell. 2010;17(2):186–97.PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society of Hematology 2012

Authors and Affiliations

  • Hui Yang
    • 1
  • Hui Liang
    • 1
  • Jing-song Yan
    • 2
  • Rong Tao
    • 1
  • Si-guo Hao
    • 1
  • Li-yuan Ma
    • 1
  1. 1.Department of Hematology, Xin Hua HospitalAffiliated to Shanghai Jiao Tong University (SJTU) School of MedicineShanghaiChina
  2. 2.Department of HematologyThe Second Affiliated Hospital of Dalian Medical UniversityDalianChina

Personalised recommendations